Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amodiaquine Hydrochloride

FDA-approved product (tablet, oral), marketed as Camoquin Hydrochloride.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Amodiaquine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Aminoquinolines
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BA06

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis14.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 0 of 1 lab record
Open Amodiaquine Hydrochloride in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amodiaquine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar

    NCT06923592 · start 2025-05-12

    Registered record
    Registry ID
    NCT06923592
    Conditions
    Malaria Vivax; Malaria Falciparum; Plasmodium Vivax; Plasmodium Falciparum
    Interventions
    PvSeroTAT; Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-05-12
    Completion
    2027-04-28
    Enrolment
    19,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria Vivax; Malaria Falciparum; Plasmodium Vivax; Plasmodium Falciparum
    InterventionPvSeroTAT; Control
    PhasePhase 3
    Registry statusRecruiting

  • Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi

    NCT06083688 · start 2024-10-14

    Registered record
    Registry ID
    NCT06083688
    Conditions
    Malaria,Falciparum; Anemia in Children
    Interventions
    Dihydroartemisinin-Piperaquine; Chloroquine; Sulfadoxine-pyrimethamine-amodiaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-10-14
    Completion
    2026-01-14
    Enrolment
    788

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria,Falciparum; Anemia in Children
    InterventionDihydroartemisinin-Piperaquine; Chloroquine; Sulfadoxine-pyrimethamine-amodiaquine
    PhasePhase 4
    Registry statusCompleted

  • Chemoprevention Efficacy Study Nigeria

    NCT05979896 · start 2023-07-28

    Registered record
    Registry ID
    NCT05979896
    Conditions
    Malaria
    Interventions
    Standard age based SPAQ administration for SMC
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-07-28
    Completion
    2024-05-15
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionStandard age based SPAQ administration for SMC
    PhasePhase 4
    Registry statusUnknown

  • Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Liberia

    NCT06300970 · start 2022-08-09

    Registered record
    Registry ID
    NCT06300970
    Conditions
    Plasmodium Falciparum; Malaria; Uncomplicated Malaria
    Interventions
    Amodiaquine-artesunate (ASAQ); Artemether+Lumefantrine (AL)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-08-09
    Completion
    2023-08-16
    Enrolment
    352

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum; Malaria; Uncomplicated Malaria
    InterventionAmodiaquine-artesunate (ASAQ); Artemether+Lumefantrine (AL)
    PhasePhase 4
    Registry statusCompleted

  • In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Pironaridine-Artesunate in Mozambique

    NCT05343312 · start 2022-03-16

    Registered record
    Registry ID
    NCT05343312
    Conditions
    Malaria
    Interventions
    AL (Coartem); AS-AQ (Carsucam); DHP; PA
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-03-16
    Completion
    2025-07-30
    Enrolment
    870

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionAL (Coartem); AS-AQ (Carsucam); DHP; PA
    PhasePhase 4
    Registry statusCompleted

  • Association Between Drug Levels, Malaria, and Antimalarial Resistance in the Setting of Seasonal Malaria Chemoprevention

    NCT04969185 · start 2021-08-16

    Registered record
    Registry ID
    NCT04969185
    Conditions
    Malaria,Falciparum
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-08-16
    Completion
    2023-05-23
    Enrolment
    310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria,Falciparum
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)

    NCT03939104 · start 2021-06-30

    Registered record
    Registry ID
    NCT03939104
    Conditions
    Plasmodium Falciparum Malaria (Uncomplicated)
    Interventions
    Artemether-lumefantrine+amodiaquine; Artemether-lumefantrine+placebo; Artesunate-mefloquine+piperaquine; Artesunate-mefloquine+placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-06-30
    Completion
    2023-01-28
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum Malaria (Uncomplicated)
    InterventionArtemether-lumefantrine+amodiaquine; Artemether-lumefantrine+placebo; Artesunate-mefloquine+piperaquine; Artesunate-mefloquine+placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo

    NCT04618523 · start 2020-10-26

    Registered record
    Registry ID
    NCT04618523
    Conditions
    Malaria
    Interventions
    Artesunate-amodiaquine; Artemether-lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-10-26
    Completion
    2022-02-08
    Enrolment
    1,117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionArtesunate-amodiaquine; Artemether-lumefantrine
    PhasePhase 4
    Registry statusCompleted

  • A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.

    NCT03923725 · start 2020-09-01

    Registered record
    Registry ID
    NCT03923725
    Conditions
    Plasmodium Falciparum Malaria (Uncomplicated)
    Interventions
    Artemether-lumefantrine+ Amodiaquine (AL+AQ); Artemether-lumefantrine + placebo (AL+PBO); Artesunate-mefloquine+piperaquine (AS-MQ+PPQ); Artesunate-mefloquine+placebo (AS-MQ+PBO)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-09-01
    Completion
    2024-03-15
    Enrolment
    2,583

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum Malaria (Uncomplicated)
    InterventionArtemether-lumefantrine+ Amodiaquine (AL+AQ); Artemether-lumefantrine + placebo (AL+PBO); Artesunate-mefloquine+piperaquine (AS-MQ+PPQ); Artesunate-mefloquine+placebo (AS-MQ+PBO)
    PhasePhase 3
    Registry statusCompleted

  • Health Systems Implementation and Molecular Surveillance of Multiple First-Line Treatments for Uncomplicated Malaria in Western Kenya

    NCT07362498 · start 2020-06-01

    Registered record
    Registry ID
    NCT07362498
    Conditions
    Malaria Falciparum
    Interventions
    Artemether + Lumefantrine; Dihydroartemisin-piperaquine; Artesunate-Amodiaquine (AS-AQ); Pyronaridine - artesunate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-06-01
    Completion
    2024-01-31
    Enrolment
    316

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria Falciparum
    InterventionArtemether + Lumefantrine; Dihydroartemisin-piperaquine; Artesunate-Amodiaquine (AS-AQ); Pyronaridine - artesunate
    PhaseNot recorded
    Registry statusCompleted

  • Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde

    NCT04565184 · start 2019-05-09

    Registered record
    Registry ID
    NCT04565184
    Conditions
    Malaria,Falciparum
    Interventions
    Artesunate-amodiaquine combination; Artemether, Lumefantrine Drug Combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-05-09
    Completion
    2020-11-30
    Enrolment
    242

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria,Falciparum
    InterventionArtesunate-amodiaquine combination; Artemether, Lumefantrine Drug Combination
    PhasePhase 4
    Registry statusCompleted

  • Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)

    NCT03178643 · start 2018-01-23

    Registered record
    Registry ID
    NCT03178643
    Conditions
    Malaria,Falciparum
    Interventions
    Proguanil Oral Tablet; Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ); Dihydroartemisinin-Piperaquine (DP)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-01-23
    Completion
    2020-12-16
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria,Falciparum
    InterventionProguanil Oral Tablet; Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ); Dihydroartemisinin-Piperaquine (DP)
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Artesunate + Amodiaquine With SLD of Primaquine for Treatment of Falciparum Malaria in Zanzibar

    NCT03773536 · start 2017-05-09

    Registered record
    Registry ID
    NCT03773536
    Conditions
    Plasmodium Falciparum Malaria
    Interventions
    Artesunate-amodiaquine given with single low dose primaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-05-09
    Completion
    2017-09-25
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlasmodium Falciparum Malaria
    InterventionArtesunate-amodiaquine given with single low dose primaquine
    PhasePhase 4
    Registry statusCompleted

  • Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ)

    NCT03143218 · start 2017-04-17

    Registered record
    Registry ID
    NCT03143218
    Conditions
    Malaria,Falciparum; Children, Only
    Interventions
    RABIPUR®; RTS,S/AS01; SMC with SP+AQ; SMC placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-04-17
    Completion
    2020-03-31
    Enrolment
    5,920

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria,Falciparum; Children, Only
    InterventionRABIPUR®; RTS,S/AS01; SMC with SP+AQ; SMC placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo

    NCT02940756 · start 2017-03-15

    Registered record
    Registry ID
    NCT02940756
    Conditions
    Malaria
    Interventions
    artesunate-amodiaquine; artemether-lumefantrine; Dihydroartemisinine-piperaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-03-15
    Completion
    2018-01-02
    Enrolment
    1,615

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    Interventionartesunate-amodiaquine; artemether-lumefantrine; Dihydroartemisinine-piperaquine
    PhasePhase 4
    Registry statusCompleted